Page last updated: 2024-11-09

urb 597

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester: a fatty acid amide hydrolase inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1383884
CHEMBL ID184238
CHEBI ID188061
SCHEMBL ID93842
MeSH IDM0484841

Synonyms (72)

Synonym
HY-10864
smr000524783
MLS001210199
3'-carbamoylbiphenyl-3-yl cyclohexylcarbamate
cyclohexyl-carbamic acid 3'-carbamoyl-biphenyl-3-yl ester
NCGC00165915-01
urb597 ,
faah inhibitor ii
cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester
3-(3-carbamoylphenyl)phenyl n-cyclohexylcarbamate
urb-597
bdbm26739
urb 597
chembl184238 ,
ZINC01238258
org-231295
kds-4103
AKOS000674060
546141-08-6
CHEBI:188061
[3-(3-carbamoylphenyl)phenyl] n-cyclohexylcarbamate
px47lb88fo ,
unii-px47lb88fo
3'-carbamoyl-biphenyl-3-yl cyclohexylcarbamate
A830267
HMS2844K18
3'-carbamoyl-[1,1'-biphenyl]-3-yl cyclohexylcarbamate
NCGC00165915-03
CS-0266
S2631
carbamic acid, n-cyclohexyl-, 3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl ester
c20h22n2o3
gtpl4339
CCG-207886
SCHEMBL93842
MLS006012031
c16h23n5o.c4h4o4
ROFVXGGUISEHAM-UHFFFAOYSA-N
cyclohexylcarbamic acid 3'-(aminocarbonyl)-[1,1'-biphenyl]-3-yl ester
cyclohexylcarbamic acid 3'-(aminocarbonyl)-[1,1'-biphenyl]-3- yl ester
HB2365
AC-26873
HMS3648C09
3'-(aminocarbonyl)-[1,1'-biphenyl]-3-yl cyclohexylcarbamate
DTXSID70203046
3'-(aminocarbonyl)(1,1'-biphenyl)-3-yl n-cyclohexylcarbamate
carbamic acid, n-cyclohexyl-, 3'-(aminocarbonyl)(1,1'-biphenyl)-3-yl ester
mfcd05863934
carbamic acid, cyclohexyl-, 3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl ester
J-523541
n-cyclohexylcarbamc acd 3'-(amnocarbonyl)[1,1'-bphenyl]-3-yl ester
EX-A769
HMS3656B07
urb597, >=98% (hplc), powder
sr-01000342602
SR-01000342602-1
SW219633-1
3'-carbamoyl-biphenyl-3-yl-cyclohexylcarbamate
HB1800
2-[(5-methoxy-1h-indol-3-yl)methyle ne]-n-pentyl-hydrazinecarboximidamide maleate
faah inhibitor ii - cas 546141-08-6
urb597 (kds-4103)
FT-0700483
3'-carbamoylbiphenyl 3-ylcyclohexylcarbamate
AS-18410
SR-01000342602-3
BCP27727
Q7865591
HMS3884N12
3-(3-aminocarbonyl)[1,1-biphenyl]-3-yl)-cyclohexylcarbamat
BU140504
3'-(3-aminocarbonyl)[1,1'-biphenyl]-3-yl)-cyclohexylcarbamat

Research Excerpts

Actions

ExcerptReferenceRelevance
"URB 597 did not increase the potency of anandamide to attenuate the rimonabant-discriminative stimulus."( The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeys.
McMahon, LR; Stewart, JL, 2011
)
1.36

Toxicity

ExcerptReferenceRelevance
" Cisplatin produces a cumulative toxic effect on peripheral nerves, and 30-40% of cancer patients receiving this agent experience pain."( Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy.
Harding-Rose, C; Khasabov, S; Khasabova, IA; Paz, J; Seybold, VS; Simone, DA, 2012
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
" Additional experiments examined these compounds in combination with morphine."( Effects of alterations in cannabinoid signaling, alone and in combination with morphine, on pain-elicited and pain-suppressed behavior in mice.
Dykstra, LA; Miller, LL; Picker, MJ; Schmidt, KT; Umberger, MD, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Oral dosing with URB597 achieved significant, albeit transient, drug levels in plasma, inhibited brain FAAH activity, and elevated spinal cord anandamide content."( The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice.
Calignano, A; Compton, TR; Duranti, A; La Rana, G; Loverme, J; Mor, M; Parrott, J; Piomelli, D; Russo, R; Tarzia, G; Tontini, A, 2007
)
0.34
" Substantial recovery of cholinesterase activity was noted at both 8 and 29days after dosing but significant inhibition was still noted in some brain regions at the latest time-point."( Behavioral sequelae following acute diisopropylfluorophosphate intoxication in rats: comparative effects of atropine and cannabinomimetics.
Liu, J; Nallapaneni, A; Pope, CN; Wright, LK,
)
0.13
"05-10 μg/mouse) produced antidepressant-like effect dose-dependently, whereas influenced the MBB in a biphasic manner (produced a U-shaped dose-response curve)."( Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice.
Jain, NS; Manna, SS; Umathe, SN, 2011
)
0.37
"Effects of pre-treatment with a single dose, versus 4 day repeated dosing with the selective FAAH inhibitor, URB597 (i."( Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system.
Alexander, SP; Barrett, DA; Bennett, AJ; Burston, J; Chapman, V; Kendall, DA; Norris, LM; Okine, BN; Patel, A; Woodhams, S, 2012
)
0.38
" Whether repeated dosing would achieve greater protection remains to be examined."( Endocannabinoid degradation inhibition improves neurobehavioral function, blood-brain barrier integrity, and neuroinflammation following mild traumatic brain injury.
Impastato, RA; Katz, PS; Molina, PE; Rogers, EK; Sulzer, JK; Teng, SX, 2015
)
0.42
" Both FAAH inhibitors: (1) blocked FAAH activity in brain and liver, increasing levels of endogenous ligands for cannabinoid and α-type peroxisome proliferator-activated (PPAR-α) receptors; (2) shifted nicotine self-administration dose-response functions in a manner consistent with reduced nicotine reward; (3) blocked reinstatement of nicotine seeking induced by reexposure to either nicotine priming or nicotine-associated cues; and (4) had no effect on cocaine or food self-administration."( Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse.
Armirotti, A; Auber, A; Bandiera, T; Barnes, C; Bertorelli, R; Chefer, SI; Goldberg, SR; Justinova, Z; Mascia, P; Moreno-Sanz, G; Panlilio, LV; Piomelli, D; Redhi, GH; Secci, ME; Yasar, S, 2015
)
0.42
" Dose-response curves had inverted U shapes, with peak response rates occurring at a dose of 10 μg/kg/injection."( Self-administration of the anandamide transport inhibitor AM404 by squirrel monkeys.
Goldberg, SR; Justinova, Z; Makriyannis, A; Redhi, GH; Scherma, M; Schindler, CW; Vadivel, SK, 2016
)
0.43
" To further investigate the specificity of effects on partner preference, we repeated our URB597 dosing regimen on an additional group of females and tested their anxiety-related behavior in both an elevated-plus maze and a light/dark test."( Effects of systemic endocannabinoid manipulation on social and exploratory behavior in prairie voles (Microtus ochrogaster).
Bales, KL; Simmons, TC; Singh, ALK, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
biphenylsBenzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (20)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency39.81070.044717.8581100.0000AID485294
Chain A, Ferritin light chainEquus caballus (horse)Potency7.07955.623417.292931.6228AID485281
LuciferasePhotinus pyralis (common eastern firefly)Potency23.93410.007215.758889.3584AID588342
glp-1 receptor, partialHomo sapiens (human)Potency11.22020.01846.806014.1254AID624417
ATAD5 protein, partialHomo sapiens (human)Potency20.58780.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686978
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency26.83700.01237.983543.2770AID1645841
IDH1Homo sapiens (human)Potency29.09290.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency63.09570.035520.977089.1251AID504332
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty-acid amide hydrolase 1Homo sapiens (human)IC50 (µMol)0.21300.00020.59827.0000AID1053388; AID1071860; AID1204560; AID1204563; AID1204564; AID1204565; AID1298501; AID1298614; AID1363884; AID1363885; AID1373459; AID1798724; AID1798725; AID1798726; AID1798727; AID1800329; AID1833693; AID346666; AID412540; AID412541; AID412542; AID412543; AID430485; AID430491; AID590553; AID602610; AID612783; AID669785; AID690260; AID697523; AID726796; AID743616
Fatty-acid amide hydrolase 1Mus musculus (house mouse)IC50 (µMol)0.00460.00461.07755.9000AID690260
Coagulation factor XIII A chainHomo sapiens (human)IC50 (µMol)0.02770.00190.01720.0590AID1204560; AID1204565
Prostaglandin G/H synthase 1Ovis aries (sheep)IC50 (µMol)100.00000.00032.177410.0000AID1282661
Bifunctional epoxide hydrolase 2Homo sapiens (human)IC50 (µMol)1.10000.00000.54509.1000AID1373458
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)100.00000.00010.995010.0000AID1282662
Fatty-acid amide hydrolase 1Rattus norvegicus (Norway rat)IC50 (µMol)0.03650.00051.33138.0000AID1507767; AID1507768; AID1525775; AID1681845; AID242504; AID266504; AID363656; AID426438; AID430487; AID430488; AID460725; AID590552; AID618766; AID637229; AID637230; AID637232; AID703163; AID743631
Fatty-acid amide hydrolase 1Rattus norvegicus (Norway rat)Ki1.00200.00060.16192.0000AID1799539; AID412539
Fatty-acid amide hydrolase 2Homo sapiens (human)IC50 (µMol)0.00500.00500.00920.0134AID1363927
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily A member 1Homo sapiens (human)EC50 (µMol)26,993.92000.00033.166210.0000AID1549771; AID1549789; AID482143; AID743737
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (90)

Processvia Protein(s)Taxonomy
fatty acid catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
arachidonic acid metabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
positive regulation of vasoconstrictionFatty-acid amide hydrolase 1Homo sapiens (human)
monoacylglycerol catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
monoatomic ion transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellular calcium ion homeostasisTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cell surface receptor signaling pathwayTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to coldTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to xenobiotic stimulusTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic cyclic compoundTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to hydrogen peroxideTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
blood coagulationCoagulation factor XIII A chainHomo sapiens (human)
peptide cross-linkingCoagulation factor XIII A chainHomo sapiens (human)
blood coagulation, fibrin clot formationCoagulation factor XIII A chainHomo sapiens (human)
response to toxic substanceBifunctional epoxide hydrolase 2Homo sapiens (human)
positive regulation of gene expressionBifunctional epoxide hydrolase 2Homo sapiens (human)
dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
cholesterol homeostasisBifunctional epoxide hydrolase 2Homo sapiens (human)
stilbene catabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
phospholipid dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
regulation of cholesterol metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
lipid catabolic processFatty-acid amide hydrolase 2Homo sapiens (human)
arachidonic acid metabolic processFatty-acid amide hydrolase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (25)

Processvia Protein(s)Taxonomy
protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
phospholipid bindingFatty-acid amide hydrolase 1Homo sapiens (human)
fatty acid amide hydrolase activityFatty-acid amide hydrolase 1Homo sapiens (human)
identical protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
acylglycerol lipase activityFatty-acid amide hydrolase 1Homo sapiens (human)
amidase activityFatty-acid amide hydrolase 1Homo sapiens (human)
calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
temperature-gated cation channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
protein-glutamine gamma-glutamyltransferase activityCoagulation factor XIII A chainHomo sapiens (human)
protein bindingCoagulation factor XIII A chainHomo sapiens (human)
metal ion bindingCoagulation factor XIII A chainHomo sapiens (human)
magnesium ion bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide hydrolase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
toxic substance bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
10-hydroxy-9-(phosphonooxy)octadecanoate phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lipid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
protein homodimerization activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lysophosphatidic acid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
fatty acid amide hydrolase activityFatty-acid amide hydrolase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneFatty-acid amide hydrolase 1Homo sapiens (human)
cytoskeletonFatty-acid amide hydrolase 1Homo sapiens (human)
organelle membraneFatty-acid amide hydrolase 1Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
stereocilium bundleTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
extracellular regionCoagulation factor XIII A chainHomo sapiens (human)
extracellular spaceCoagulation factor XIII A chainHomo sapiens (human)
platelet alpha granule lumenCoagulation factor XIII A chainHomo sapiens (human)
collagen-containing extracellular matrixCoagulation factor XIII A chainHomo sapiens (human)
blood microparticleCoagulation factor XIII A chainHomo sapiens (human)
transferase complexCoagulation factor XIII A chainHomo sapiens (human)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomal matrixBifunctional epoxide hydrolase 2Homo sapiens (human)
cytosolBifunctional epoxide hydrolase 2Homo sapiens (human)
extracellular exosomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
lipid dropletFatty-acid amide hydrolase 2Homo sapiens (human)
membraneFatty-acid amide hydrolase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (219)

Assay IDTitleYearJournalArticle
AID1363886Ratio of kinact to Ki for FAAH (unknown origin)2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors.
AID1053388Inhibition of human recombinant FAAH overexpressed in African green monkey COS7 cells using [3H]-anandamide as substrate preincubated for 10 mins before substrate addition measured after 10 mins by liquid scintillation counting analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Chiral 1,3,4-oxadiazol-2-ones as highly selective FAAH inhibitors.
AID1373461Time dependent inhibition of human recombinant soluble epoxide hydrolase expressed in baculovirus-infected High Five cells S9 fraction pre-incubated for 10 to 70 mins before CMNPC substrate addition by fluorescence based assay relative to untreated contro2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID590552Inhibition of rat FAAH assessed as hydrolysis of anandamido-amino-methyl-cumarin2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.
AID743616Inhibition of FAAH (unknown origin)2013European journal of medicinal chemistry, May, Volume: 63(4-Phenoxyphenyl)tetrazolecarboxamides and related compounds as dual inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).
AID618765Metabolic stability of the compound in Wistar rat liver S9 fraction assessed as half life at 1 uM by RP-HPLC analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability.
AID1071859Antiinflammatory activity in C57/BL6 mouse DSS-induced colitis model assessed as reversal of DSS-induced body weight loss at 10 mg/kg, ip for 8 days relative to control2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Switching cannabinoid response from CB(2) agonists to FAAH inhibitors.
AID1525775Inhibition of FAAH in Wistar rat brain intact neurons assessed as reduction in [3H]anandamide hydrolysis using [3H]anandamide as substrate preincubated for 10 mins followed by substrate addition and measured after 4 mins by HPLC/MS analysis2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
New Approaches to Cancer Therapy: Combining Fatty Acid Amide Hydrolase (FAAH) Inhibition with Peroxisome Proliferator-Activated Receptors (PPARs) Activation.
AID1282661Inhibition of ovine COX1 assessed as production of PGF2-alpha preincubated with compound followed by the addition of 5 uM arachidonic acid as substrate by enzyme immunoassay2016European journal of medicinal chemistry, Feb-15, Volume: 109Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies.
AID363662Inhibition of rat liver esterase assessed as ester (4-nitrophenyl-acetate) hydrolysis at 10 uM after 30 mins2008Bioorganic & medicinal chemistry letters, Sep-01, Volume: 18, Issue:17
Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase.
AID553228Inhibition of fluorophosphonate-reactive 55/65 kDa serine proteases in mouse liver soluble proteomes at 100 uM by competitive activity based protein profiling2011ACS medicinal chemistry letters, Feb-10, Volume: 2, Issue:2
Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.
AID346666Inhibition of human FAAH2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors.
AID1313244Ratio of IC50 at pH7.4 to pH 9 for FAAH in rat brain membrane2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents.
AID1385744Intrinsic agonist activity at human MT1 receptor expressed in rat NIH/3T3 cell membranes assessed as induction of G protein activation incubated for 30 mins by [35S]GTPgammaS binding assay relative to melatonin
AID1609756Inhibition of human ERG expressed in HEK293 cells incubated for 72 hrs by patch clamp assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems.
AID602610Inhibition of human recombinant FAAH expressed in Escherichia coli using [3H]AEA substrate incubated at 37 degC for 10 mins by liquid scintillation counting method2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis.
AID637230Inhibition of rat intact neuron FAAH2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Design, synthesis and evaluation of polar head group containing 2-keto-oxazole inhibitors of FAAH.
AID1585164Inhibition of human recombinant MAGL at 10 uM using 1,3-dihydroxypropan-2-yl 4-pyren-1-ylbutanoate as substrate after 45 mins by fluorescence-based HPLC analysis2018European journal of medicinal chemistry, Dec-05, Volume: 160Tetrazolylpropan-2-ones as inhibitors of fatty acid amide hydrolase: Studies on structure-activity relationships and metabolic stability.
AID1549771Agonist activity at human TRPA1 expressed in HEK293 cells assessed as increase in calcium influx by Fluo-4-AM dye based fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID1363884Inhibition of recombinant human N-terminal -His6 tagged FAAH (32 to 579 residues) expressed in Escherichia coli BL21 preincubated for 60 mins followed by olamide substrate addition measured every 10 sec intervals for 30 mins by spectrophotometry2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors.
AID703155Inhibition of mouse DAGLalpha expressed in HEK293T cell membrane using [14C]SAG substrate at 10000 nM by scintillation counting based radio-TLC assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Assay and inhibition of diacylglycerol lipase activity.
AID426454Inhibition of FAAH-mediated hydrolysis of [3H]anandamide in rat RBL2H3 cells at 0.01 uM relative to control2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors.
AID553225Inhibition of FAAH in mouse brain membrane proteomes at 100 uM by competitive activity based protein profiling2011ACS medicinal chemistry letters, Feb-10, Volume: 2, Issue:2
Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.
AID618762Chemical stability of the compound in 0.01 M PBS assessed as compound remaining at pH 7.0 by HPLC analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability.
AID1373475Inhibition of FAAH in horse brain microsomes using OMP substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID697497Analgesic activity in rat assessed as increase in paw withdrawal threshold at 50 mg/kg, po2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Discovery of potent inhibitors of human and mouse fatty acid amide hydrolases.
AID1373458Inhibition of human recombinant soluble epoxide hydrolase expressed in baculovirus-infected High Five cells S9 fraction using CMNPC substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID590553Inhibition of human FAAH assessed as hydrolysis of anandamido-amino-methyl-cumarin2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.
AID703157Inhibition of mouse DAGLalpha expressed in HEK293T cell membrane using [14C]SAG substrate at 100 nM by scintillation counting based radio-TLC assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Assay and inhibition of diacylglycerol lipase activity.
AID697525Inhibition of mouse FAAH isolated from brain homogenate using [3H-ethanolamine]AEA as substrate incubated for 20 mins prior to substrate addition measured after 15 mins by beta counting analysis2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Discovery of potent inhibitors of human and mouse fatty acid amide hydrolases.
AID1506804Inhibition of FAAH in rat brain microsomes assessed as reduction in enzyme-mediated 4-pyren-1-ylbutanoic acid release using N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide as substrate incubated fro 60 mins by reversed phase HPLC method2017MedChemComm, Mar-01, Volume: 8, Issue:3
(Indolylalkyl)piperidine carbamates as inhibitors of fatty acid amide hydrolase (FAAH).
AID1385746Intrinsic agonist activity at human MT2 receptor expressed in rat NIH/3T3 cell membranes assessed as induction of G protein activation incubated for 30 mins by [35S]GTPgammaS binding assay relative to melatonin
AID1071856Antiinflammatory activity in C57/BL6 mouse DSS-induced colitis model assessed as decrease in mononuclear and granulocytic infiltrate level at 10 mg/kg, ip for 8 days by MGG staining-based assay2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Switching cannabinoid response from CB(2) agonists to FAAH inhibitors.
AID430491Inhibition of FAAH2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas.
AID430488Inhibition of rat FAAH incubated 3 hrs prior to addition of arachidonyl-amino-methyl-coumarin amide2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas.
AID1204563Inhibition of human recombinant FAAH using AMC arachidonoyl amide as substrate preincubated with protein for 0 min followed by substrate addition by fluorescence assay2015European journal of medicinal chemistry, Jun-05, Volume: 97Pyrazole phenylcyclohexylcarbamates as inhibitors of human fatty acid amide hydrolases (FAAH).
AID1609754Displacement of [3H]-spiperone from human D2 receptor expressed in CHO cells co-expressing Galpha16 incubated for 120 mins by liquid scintillation counting method2019European journal of medicinal chemistry, Dec-01, Volume: 183Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems.
AID722132Inhibition of FAAH-mediated [3H]anandamide hydrolysis in rat brain homogenate assessed as [3H]ethanolamine production at 0.1 nM incubated for 60 mins prior to substrate addition measured after 10 mins by liquid scintillation counting analysis relative to 2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Radiosynthesis and evaluation of [¹¹C-carbonyl]-labeled carbamates as fatty acid amide hydrolase radiotracers for positron emission tomography.
AID1298503Cytotoxicity against human HEK293 cells assessed as growth inhibition at 10 uM after 72 hrs by MTS assay relative to control2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Design, synthesis and biological evaluation of potent FAAH inhibitors.
AID1298500Inhibition of human recombinant FAAH expressed in sf21 cells using AMC-AA as substrate at 10 uM preincubated for 15 mins followed by substrate addition measured after 2 hrs by spectrophotometric analysis relative to control2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Design, synthesis and biological evaluation of potent FAAH inhibitors.
AID1373474Inhibition of FAAH in dog brain microsomes using OMP substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID1334995Inhibition of FAAH in rat brain microsomes using N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide as substrate after 60 mins by fluorescence-based reversed phase HPLC analysis2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
1-Heteroarylpropan-2-ones as inhibitors of fatty acid amide hydrolase: Studies on structure-activity relationships and metabolic stability.
AID695704Inhibition of MAGL in mouse B16 cells assessed as increase in 2-arachidonoylglycerol level at 10 uM after 8 hrs by isotope dilution HPLC-MS method2012Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12
Synthesis and pharmacological evaluation of 2,4-dinitroaryldithiocarbamate derivatives as novel monoacylglycerol lipase inhibitors.
AID1507768Inhibition of rat brain FAAH using [3H]AEA as substrate preincubated for 10 mins at pH 82017European journal of medicinal chemistry, Aug-18, Volume: 136Novel propanamides as fatty acid amide hydrolase inhibitors.
AID637229Inhibition of rat brain membrane FAAH2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Design, synthesis and evaluation of polar head group containing 2-keto-oxazole inhibitors of FAAH.
AID618766Displacement of [3H]-anandamide from rat brain FAAH after 30 mins by scintillation counting2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability.
AID1373459Inhibition of human FAAH expressed in baculovirus-infected High Five cells S9 fraction using OMP substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID426456Inhibition of FAAH-mediated hydrolysis of [3H]anandamide in rat RBL2H3 cells at 1 uM relative to control2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors.
AID703158Inhibition of mouse DAGLalpha expressed in HEK293T cell membrane using [14C]SAG substrate at 10 nM by scintillation counting based radio-TLC assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Assay and inhibition of diacylglycerol lipase activity.
AID743737Agonist activity at GDH-tagged human TRPA1 receptor expressed in HEK293F cells assessed as increase in intracellular Ca2+ concentration by FLIPR assay2013European journal of medicinal chemistry, May, Volume: 63Biaryl tetrazolyl ureas as inhibitors of endocannabinoid metabolism: modulation at the N-portion and distal phenyl ring.
AID1385747Inhibition of FAAH1 in Wistar rat brain homogenates using [3H]anandamide as substrate incubated for 30 mins by liquid scintillation counting method
AID743625Inhibition of MAGL (unknown origin)-mediated anandamide hydrolysis at 30 uM2013European journal of medicinal chemistry, May, Volume: 63(4-Phenoxyphenyl)tetrazolecarboxamides and related compounds as dual inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).
AID1053353Inhibition of FAAH in rat RBL2H3 cells assessed as blockade of [3H]-anandamide uptake at 0.1 uM incubated for 15 mins prior to [3H]-anandamide addition measured after 10 mins by scintillation spectroscopic analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Chiral 1,3,4-oxadiazol-2-ones as highly selective FAAH inhibitors.
AID1298501Inhibition of human recombinant FAAH expressed in sf21 cells using AMC-AA as substrate preincubated for 15 mins followed by substrate addition measured after 2 hrs by spectrophotometric analysis2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Design, synthesis and biological evaluation of potent FAAH inhibitors.
AID722125Half life in phosphate buffer at pH 7.4 by HPLC analysis2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Radiosynthesis and evaluation of [¹¹C-carbonyl]-labeled carbamates as fatty acid amide hydrolase radiotracers for positron emission tomography.
AID1385743Displacement of [125I]iodomelatonin from human MT1 receptor expressed in rat NIH/3T3 cell membranes incubated for 90 mins by Cheng-Prusoff equation analysis
AID1441168Displacement of [3H]anandamide from FAAH in rat brain membranes after 30 mins by liquid scintillation counting2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Design, Synthesis, Structure-Activity Relationship Studies, and Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) Modeling of a Series of O-Biphenyl Carbamates as Dual Modulators of Dopamine D3 Receptor and Fatty Acid Amide Hydrolas
AID461312Inhibition of FAAH-mediated [3H]AEA uptake in rat RBL2H3 cells at 1 uM by liquid scintillation spectroscopy2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Synthesis and evaluation of paracetamol esters as novel fatty acid amide hydrolase inhibitors.
AID1549811Agonist activity at human TRPA1 Phe909Ala mutant expressed in HEK293 cells assessed as Ca2+ influx at 100 uM by fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID426443Inhibition of FAAH-mediated hydrolysis of [3H]2-arachidonoylglycerol in rat RBL2H3 cells at >0.03 uM2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors.
AID426812Inhibition of histidine6-tagged FAAH from human liver proteomes at 10 to 100 uM2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH).
AID618764Metabolic stability of the compound in Wistar rat plasma assessed as half life at 1 uM by RP-HPLC analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability.
AID722129Inhibition of FAAH-mediated [3H]anandamide hydrolysis in rat brain homogenate assessed as [3H]ethanolamine production at 100 nM incubated for 60 mins prior to substrate addition measured after 10 mins by liquid scintillation counting analysis relative to 2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Radiosynthesis and evaluation of [¹¹C-carbonyl]-labeled carbamates as fatty acid amide hydrolase radiotracers for positron emission tomography.
AID1313242Inhibition of FAAH in rat brain membrane at pH 9 using N-arachidonoyl-[14C]-ethanolamine as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by scintillation counting method2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents.
AID723532Irreversible inhibition of human recombinant FAAH using [3H]AEA as substrate incubated up to 90 mins by compound dilution method2013European journal of medicinal chemistry, Feb, Volume: 60An unprecedented reversible mode of action of β-lactams for the inhibition of human fatty acid amide hydrolase (hFAAH).
AID612778In vivo inhibition of rat FAAH at 0.3 mg/kg, ip after 16 hrs2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH).
AID426438Inhibition of FAAH in Wistar rat cerebral membrane by liquid scintillation counting2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors.
AID1681845Inhibition of FAAH in rat brain membrane using N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide as substrate measured after 60 mins by reverse-phase HPLC-based fluorescence assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Acylated 1
AID412540Inhibition of human recombinant FAAH expressed in HEK293 cells by [3H]anandamide carbon filtration assay2009Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors.
AID1506806Metabolic stability in porcine blood plasma assessed as parent compound remaining incubated fro 30 mins by HPLC and MS-detection based method2017MedChemComm, Mar-01, Volume: 8, Issue:3
(Indolylalkyl)piperidine carbamates as inhibitors of fatty acid amide hydrolase (FAAH).
AID412539Inhibition of rat cortex FAAH by [3H]anandamide carbon filtration assay2009Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors.
AID1185870Inhibition of FAAH in rat brain membranes assessed as reduction in [14C] anandamide hydrolysis at 0.1 uM by scintillation counting method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
AID426455Inhibition of FAAH-mediated hydrolysis of [3H]anandamide in rat RBL2H3 cells at 0.1 uM relative to control2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors.
AID703171Inhibition of human DAGLalpha expressed in HEK293T cell membrane using [14C]SAG substrate at 10 uM using JZL184 pretreated protein in detergent free solution by FRET assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Assay and inhibition of diacylglycerol lipase activity.
AID697526Inhibition of mouse FAAH isolated from brain homogenate using [3H-ethanolamine]AEA as substrate assessed as residual activity at 10 uM incubated for 20 mins prior to substrate addition measured after 15 mins by beta counting analysis2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Discovery of potent inhibitors of human and mouse fatty acid amide hydrolases.
AID461313Inhibition of FAAH-mediated [3H]AEA accumulation in rat RBL2H3 cells membrane by liquid scintillation spectroscopy2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Synthesis and evaluation of paracetamol esters as novel fatty acid amide hydrolase inhibitors.
AID1282662Inhibition of recombinant human COX2 assessed as production of PGF2-alpha preincubated with compound followed by the addition of 5 uM arachidonic acid as substrate by enzyme immunoassay2016European journal of medicinal chemistry, Feb-15, Volume: 109Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies.
AID1156298Antiallodynic activity in Harlan rat spinal nerve ligation model of neuropathic pain assessed as reversal of allodynia at 21 mg/kg, po2014ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6
Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain.
AID7221281-octanol-phosphate buffer partition coefficient, log D of the compound at pH 7.42013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Radiosynthesis and evaluation of [¹¹C-carbonyl]-labeled carbamates as fatty acid amide hydrolase radiotracers for positron emission tomography.
AID242504Inhibition of [3H]anandamide binding to fatty acid amide hydrolase of rat brain membranes2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies.
AID703163Inhibition of rat histidine tagged FAAH expressed in Escherichia coli by coumarin ester substrate fluorescence assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Assay and inhibition of diacylglycerol lipase activity.
AID1298505Inhibition of FAAH in rat brain membrane using anandamide[ethanolamine-3H] as substrate assessed as reduction in [3H]-ethanolamine production incubated for 30 mins by scintillation counting method2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Design, synthesis and biological evaluation of potent FAAH inhibitors.
AID669785Inhibition of human recombinant FAAH in assessed as hydrolysis of [14C]-anandamide preincubated for 20 mins before [14C]-anandamide addition measured after 30 mins2012ACS medicinal chemistry letters, Mar-08, Volume: 3, Issue:3
The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?
AID1204560Inhibition of human recombinant FAAH using AMC arachidonoyl amide as substrate after 30 mins by fluorescence assay2015European journal of medicinal chemistry, Jun-05, Volume: 97Pyrazole phenylcyclohexylcarbamates as inhibitors of human fatty acid amide hydrolases (FAAH).
AID430487Inhibition of rat FAAH incubated 1 hr prior to addition of arachidonyl-amino-methyl-coumarin amide2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas.
AID1373471Inhibition of FAAH in mouse brain microsomes using OMP substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID363656Inhibition of rat FAAH preincubated for 20 mins2008Bioorganic & medicinal chemistry letters, Sep-01, Volume: 18, Issue:17
Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase.
AID346661Half life in mouse brain2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors.
AID412541Inhibition of human recombinant FAAH expressed in HEK293 cells preincubated for 5 mins before substrate addition by [3H]anandamide carbon filtration assay2009Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors.
AID743631Inhibition of FAAH in Sprague-Dawley rat brain microsomes assessed as N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide conversion to 4-pyren-1-ylbutanoic acid preincubated for 10 mins measured after 45 mins by HPLC analysis2013European journal of medicinal chemistry, May, Volume: 63(4-Phenoxyphenyl)tetrazolecarboxamides and related compounds as dual inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).
AID697523Inhibition of FAAH2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Discovery of potent inhibitors of human and mouse fatty acid amide hydrolases.
AID553229Inhibition of fluorophosphonate-reactive 55/65 kDa serine proteases in human liver soluble proteomes at 100 uM by competitive activity based protein profiling2011ACS medicinal chemistry letters, Feb-10, Volume: 2, Issue:2
Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.
AID430485Inhibition of human FAAH incubated 1 hr prior to addition of arachidonyl-amino-methyl-coumarin amide2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas.
AID669788Inhibition of FAAH in rat brain membranes assessed as hydrolysis of [14C]-anandamide preincubated for 20 mins before [14C]-anandamide addition measured after 30 mins2012ACS medicinal chemistry letters, Mar-08, Volume: 3, Issue:3
The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?
AID1385749Reduction in hypertonic saline solution-induced elevated intraocular pressure in New Zealand White rabbit at 1 mM dosed topically before hypertonic saline solution injection measured after 120 mins
AID266504Inhibition of Wistar rat brain FAAH2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system.
AID553222Inhibition of FAAH in human brain membrane proteomes at 10 uM by competitive activity based protein profiling2011ACS medicinal chemistry letters, Feb-10, Volume: 2, Issue:2
Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.
AID460725Inhibition of FAAH from rat brain microsomes by RP-HPLC2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A(2)alpha and fatty acid amide hydrolase.
AID1624790Inhibition of FAAH in mouse brain membrane assessed as protein band intensity at 4 uM pre-incubated for 25 mins followed by TAMRA-FP probe labeling for 5 mins by SDS-PAGE analysis relative to control2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor.
AID722131Inhibition of FAAH-mediated [3H]anandamide hydrolysis in rat brain homogenate assessed as [3H]ethanolamine production at 1 nM incubated for 60 mins prior to substrate addition measured after 10 mins by liquid scintillation counting analysis relative to co2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Radiosynthesis and evaluation of [¹¹C-carbonyl]-labeled carbamates as fatty acid amide hydrolase radiotracers for positron emission tomography.
AID1525774Inhibition of FAAH in Wistar rat brain membranes assessed as reduction in [3H]anandamide hydrolysis using [3H]anandamide as substrate preincubated for 10 mins followed by substrate addition and measured after 4 mins by HPLC/MS analysis2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
New Approaches to Cancer Therapy: Combining Fatty Acid Amide Hydrolase (FAAH) Inhibition with Peroxisome Proliferator-Activated Receptors (PPARs) Activation.
AID1624792Inhibition of ABHD6 in mouse brain membrane assessed as protein band intensity at 4 uM pre-incubated for 25 mins followed by TAMRA-FP probe labeling for 5 mins by SDS-PAGE analysis relative to control2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor.
AID412543Inhibition of human recombinant FAAH expressed in HEK293 cells preincubated for 60 mins before substrate addition by [3H]anandamide carbon filtration assay2009Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors.
AID722130Inhibition of FAAH-mediated [3H]anandamide hydrolysis in rat brain homogenate assessed as [3H]ethanolamine production at 10 nM incubated for 60 mins prior to substrate addition measured after 10 mins by liquid scintillation counting analysis relative to c2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Radiosynthesis and evaluation of [¹¹C-carbonyl]-labeled carbamates as fatty acid amide hydrolase radiotracers for positron emission tomography.
AID726796Inhibition of FAAH (unknown origin)2013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
Synthesis, SAR study, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase (FAAH) inhibitors.
AID1282660Inhibition of FAAH in Sprague-Dawley rat brain homogenates preincubated for 10 mins followed by addition of substrate measured after 30 mins by liquid scintillation counting2016European journal of medicinal chemistry, Feb-15, Volume: 109Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies.
AID1624791Inhibition of MAGL in mouse brain membrane assessed as protein band intensity at 4 uM pre-incubated for 25 mins followed by TAMRA-FP probe labeling for 5 mins by SDS-PAGE analysis relative to control2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor.
AID426452Irreversible inhibition of FAAH in Wistar rat brain homogenate at 76 nM by liquid scintillation counting2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors.
AID637232Inhibition of Sprague-Dawley rat brain microsome FAAH assessed as reduction in 4-pyren-1-ylbutanoic acid release after 60 mins by reverse phase HPLC-based fluorescence method2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Design, synthesis and evaluation of polar head group containing 2-keto-oxazole inhibitors of FAAH.
AID703169Inhibition of human DAGLalpha expressed in HEK293T cell membrane using [14C]SAG substrate at 10 uM in detergent free solution by scintillation counting based radio-TLC assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Assay and inhibition of diacylglycerol lipase activity.
AID1373472Inhibition of FAAH in rat brain microsomes using OMP substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID703150Inhibition of porcine pancreatic lipase type 2 at 10 uM by FRET assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Assay and inhibition of diacylglycerol lipase activity.
AID426451Irreversible inhibition of human MGL at 0.3 uM by liquid scintillation counting2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors.
AID1298502Cytotoxicity against human HT-29 cells assessed as growth inhibition at 10 uM after 72 hrs by MTS assay relative to control2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Design, synthesis and biological evaluation of potent FAAH inhibitors.
AID1298614Inhibition of MBP-fused human recombinant FAAH with truncated N-terminal transmembrane domain expressed in Escherichia coli T7 using D-AMC substrate measured over 40 mins by fluorescence based assay2016Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12
Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic properties.
AID1373473Inhibition of FAAH in cat brain microsomes using OMP substrate by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID1585157Metabolic stability in rat liver S9 fraction assessed as parent compound remaining after 30 mins in presence of NADPH by HPLC/MS analysis2018European journal of medicinal chemistry, Dec-05, Volume: 160Tetrazolylpropan-2-ones as inhibitors of fatty acid amide hydrolase: Studies on structure-activity relationships and metabolic stability.
AID697518Irreversible inhibition of mouse FAAH isolated from brain homogenate using [3H-ethanolamine]AEA as substrate incubated for 20 mins prior to substrate addition measured after 18 hrs by microdialysis method2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Discovery of potent inhibitors of human and mouse fatty acid amide hydrolases.
AID426813Inhibition of histidine6-tagged FAAH from human heart proteomes at 10 to 100 uM2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH).
AID1363927Inhibition of recombinant human N-terminal FLAG-tagged/C-terminal Myc-His6 tagged FAAH2 (32 to 579 residues) expressed in COS7 cell membranes2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors.
AID1373460Time dependent inhibition of human recombinant soluble epoxide hydrolase expressed in baculovirus-infected High Five cells S9 fraction pre-incubated for 10 to 70 mins before CMNPC substrate addition by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
AID1363885Inhibition of recombinant human N-terminal -His6 tagged FAAH (32 to 579 residues) expressed in Escherichia coli BL21-AI preincubated for 5 mins followed by olamide substrate addition measured every 10 sec intervals for 30 mins by spectrophotometry2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors.
AID1363878Inhibition of FAAH in Wistar rat brain membranes using [3H]-anandamide as substrate preincubated for 10 mins followed by substrate addition measured after 4 mins by liquid scintillation counting method2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors.
AID690260Irreversible inhibition of human recombinant FAAH assessed as hydrolysis of [3H]-AEA after 10 mins by liquid scintillation counting2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
SAR and LC/MS studies of β-lactamic inhibitors of human fatty acid amide hydrolase (hFAAH): evidence of a nonhydrolytic process.
AID1385748Reduction in hypertonic saline solution-induced elevated intraocular pressure in New Zealand White rabbit at 1 mM dosed topically before hypertonic saline solution injection measured after 60 mins
AID426814Inhibition of histidine6-tagged FAAH from human brain proteomes at 10 to 100 uM2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH).
AID743630Inhibition of human recombinant MAGL-mediated 1,3-dihydroxypropan-1-yl 4-pyren-1-ylbutanoate conversion to 4-pyren-1-ylbutanoic acid at 10 uM preincubated for 15 mins measured after 45 mins by HPLC analysis relative to control2013European journal of medicinal chemistry, May, Volume: 63(4-Phenoxyphenyl)tetrazolecarboxamides and related compounds as dual inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).
AID722127Percentage unbound in human plasma after 10 mins by ultrafiltration method2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Radiosynthesis and evaluation of [¹¹C-carbonyl]-labeled carbamates as fatty acid amide hydrolase radiotracers for positron emission tomography.
AID426448Inhibition of MGL in Wistar rat cerebral membrane at 1 mM by HPLC2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors.
AID703165Inhibition of rat histidine tagged FAAH expressed in Escherichia coli at 10 uM by coumarin ester substrate fluorescence assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Assay and inhibition of diacylglycerol lipase activity.
AID618763Chemical stability of the compound in 0.01 M borate buffer assessed as half life at pH 9.0 by HPLC analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability.
AID363689Inhibition of rat FAAH assessed as recovery of enzyme activity at IC80 concentration after 18 hrs at 4 degC by dialysis2008Bioorganic & medicinal chemistry letters, Sep-01, Volume: 18, Issue:17
Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase.
AID426446Inhibition of FAAH-mediated hydrolysis of [3H]anandamide in rat RBL2H3 cells at 0.001 uM relative to control2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors.
AID1549789Agonist activity at human TRPA1 expressed in HEK293F cells assessed as increase in calcium influx by FLIPR analysis2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID553223Inhibition of FAAH in human brain membrane proteomes at 100 uM by competitive activity based protein profiling2011ACS medicinal chemistry letters, Feb-10, Volume: 2, Issue:2
Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.
AID1204565Inhibition of human recombinant FAAH using AMC arachidonoyl amide as substrate preincubated with protein for 60 mins followed by substrate addition by fluorescence assay2015European journal of medicinal chemistry, Jun-05, Volume: 97Pyrazole phenylcyclohexylcarbamates as inhibitors of human fatty acid amide hydrolases (FAAH).
AID1507767Inhibition of rat brain FAAH using [3H]AEA as substrate preincubated for 10 mins at pH 62017European journal of medicinal chemistry, Aug-18, Volume: 136Novel propanamides as fatty acid amide hydrolase inhibitors.
AID1313245Cytotoxicity against human SH-SY5Y assessed as reduction in cell viability at 1 to 50 uM after 24 hrs by MTT assay2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents.
AID1609752Inhibition of FAAH in mouse brain membranes using [14C]-AEA as substrate incubated for 15 mins by scintillation counting method2019European journal of medicinal chemistry, Dec-01, Volume: 183Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems.
AID426453Reversible inhibition of FAAH in Wistar rat brain homogenate at 2.8 nM by liquid scintillation counting2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors.
AID703152Inhibition of bacterial lipoprotein lipase at 10 uM by FRET assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Assay and inhibition of diacylglycerol lipase activity.
AID1071860Inhibition of human recombinant FAAH expressed in Escherichia coli assessed as hydrolysis of [3H]-AEA2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Switching cannabinoid response from CB(2) agonists to FAAH inhibitors.
AID363690Inhibition of rat FAAH assessed as recovery of enzyme activity at IC80 concentration after 18 hrs at 22 degC by dialysis2008Bioorganic & medicinal chemistry letters, Sep-01, Volume: 18, Issue:17
Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase.
AID695705Inhibition of FAAH in mouse B16 cells assessed as increase in N-acylethanlmine level after 8 hrs by isotope dilution HPLC-MS method2012Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12
Synthesis and pharmacological evaluation of 2,4-dinitroaryldithiocarbamate derivatives as novel monoacylglycerol lipase inhibitors.
AID1585155Inhibition of FAAH in rat brain microsomes using N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide as substrate after 60 mins by fluorescence-based HPLC analysis2018European journal of medicinal chemistry, Dec-05, Volume: 160Tetrazolylpropan-2-ones as inhibitors of fatty acid amide hydrolase: Studies on structure-activity relationships and metabolic stability.
AID1833693Inhibition of human FAAH using N-(6-methoxypyridin-3-yl)octanamide as a substrate assessed as reduction in 6-methoxypyridin-3-amine formation by fluorescence microplate reader assay2021Bioorganic & medicinal chemistry, 12-01, Volume: 51Further exploration of the structure-activity relationship of dual soluble epoxide hydrolase/fatty acid amide hydrolase inhibitors.
AID703162Inhibition of human N-terminal histidine tagged full length MAGL expressed in Escherichia coli at 10 uM by by coumarin ester substrate fluorescence assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Assay and inhibition of diacylglycerol lipase activity.
AID426811Inhibition of histidine6-tagged FAAH from mouse kidney proteomes at 10 to 100 uM2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH).
AID412542Inhibition of human recombinant FAAH expressed in HEK293 cells preincubated for 30 mins before substrate addition by [3H]anandamide carbon filtration assay2009Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors.
AID404765Inhibition of FAAH in rat brain membrane assessed as [3H]anandamide hydrolysis2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates.
AID703154Inhibition of human DAGLalpha expressed in HEK293T cell membrane using [14C]SAG substrate at 10 uM in detergent free solution by FRET assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Assay and inhibition of diacylglycerol lipase activity.
AID612783Inhibition of FAAH2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH).
AID1609755Displacement of [3H]-spiperone from human D3 receptor expressed in CHO cells co-expressing Galpha16 incubated for 120 mins by liquid scintillation counting method2019European journal of medicinal chemistry, Dec-01, Volume: 183Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems.
AID703156Inhibition of mouse DAGLalpha expressed in HEK293T cell membrane using [14C]SAG substrate at 1000 nM by scintillation counting based radio-TLC assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Assay and inhibition of diacylglycerol lipase activity.
AID553224Inhibition of FAAH in mouse brain membrane proteomes at 10 uM by competitive activity based protein profiling2011ACS medicinal chemistry letters, Feb-10, Volume: 2, Issue:2
Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.
AID346662Ex vivo inhibition of FAAH activity in rat brain after 16 hrs2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors.
AID1385745Displacement of [125I]iodomelatonin from human MT2 receptor expressed in rat NIH/3T3 cell membranes incubated for 90 mins by Cheng-Prusoff equation analysis
AID1460829Inhibition of MAGL in pig brain homogenates using [3H]2-OG as substrate at 10 uM after 15 mins in presence of URB597 by liquid scintillation counting method2017Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22
Biological evaluation of pyridone alkaloids on the endocannabinoid system.
AID1910303Inhibition of FAAH in mouse brain membrane at 10 uM using TAMRA-FP serine hydrolase probe as substrate preincubated for 25 mins followed by substrate addition and measured after 25 mins SDS-PAGE analysis2022Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10
Reversible Monoacylglycerol Lipase Inhibitors: Discovery of a New Class of Benzylpiperidine Derivatives.
AID460728Inhibition of cPLA2 from human platelets at 10 uM by RP-HPLC2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A(2)alpha and fatty acid amide hydrolase.
AID1460831Inhibition of ABHD12 in mouse BV2 cells preincubated for 30 mins and subsequent addition of [3H]-2-OG substrate measured after 15 mins by liquid scintillation counting method2017Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22
Biological evaluation of pyridone alkaloids on the endocannabinoid system.
AID426810Inhibition of histidine6-tagged FAAH from mouse liver proteomes at 10 to 100 uM2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH).
AID1204564Inhibition of human recombinant FAAH using AMC arachidonoyl amide as substrate preincubated with protein for 30 mins followed by substrate addition by fluorescence assay2015European journal of medicinal chemistry, Jun-05, Volume: 97Pyrazole phenylcyclohexylcarbamates as inhibitors of human fatty acid amide hydrolases (FAAH).
AID1506805Metabolic stability in rat liver S9 fractions assessed as parent compound remaining in presence of NADPH incubated fro 30 mins by HPLC and MS-detection based method2017MedChemComm, Mar-01, Volume: 8, Issue:3
(Indolylalkyl)piperidine carbamates as inhibitors of fatty acid amide hydrolase (FAAH).
AID1313243Inhibition of FAAH in rat brain membrane at pH 7.4 using N-arachidonoyl-[14C]-ethanolamine as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by scintillation counting method2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents.
AID482143Agonist activity at human TRPA1 channel expressed in HEK293 cells assessed as increase in intracellular calcium influx2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
AID1460830Inhibition of ABHD6 in mouse BV2 cells preincubated for 30 mins and subsequent addition of [3H]-2-OG substrate measured after 15 mins by liquid scintillation counting method2017Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22
Biological evaluation of pyridone alkaloids on the endocannabinoid system.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1345254Human Fatty acid amide hydrolase-2 (N-Acylethanolamine turnover)2006The Journal of biological chemistry, Dec-01, Volume: 281, Issue:48
A second fatty acid amide hydrolase with variable distribution among placental mammals.
AID1345254Human Fatty acid amide hydrolase-2 (N-Acylethanolamine turnover)2009Anesthesia and analgesia, Jan, Volume: 108, Issue:1
Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase.
AID1345299Human Fatty acid amide hydrolase (Hydrolases)2006The Journal of biological chemistry, Dec-01, Volume: 281, Issue:48
A second fatty acid amide hydrolase with variable distribution among placental mammals.
AID1346556Human TRPA1 (Transient Receptor Potential channels)2007Molecular pharmacology, May, Volume: 71, Issue:5
Activation of TRPA1 channels by the fatty acid amide hydrolase inhibitor 3'-carbamoylbiphenyl-3-yl cyclohexylcarbamate (URB597).
AID1798726FAAH Inhibition Assay (30 min Preincubation) from Article 10.1021/bi701378g: \\Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.\\2007Biochemistry, Nov-13, Volume: 46, Issue:45
Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.
AID1798725FAAH Inhibition Assay (15 min Preincubation) from Article 10.1021/bi701378g: \\Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.\\2007Biochemistry, Nov-13, Volume: 46, Issue:45
Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.
AID1800329FAAH Activity Assay from Article 10.1021/cb500177c: \\Functionalization of u00DF-Caryophyllene Generates Novel Polypharmacology in the Endocannabinoid System.\\2014ACS chemical biology, Jul-18, Volume: 9, Issue:7
Functionalization of β-caryophyllene generates novel polypharmacology in the endocannabinoid system.
AID1798724FAAH Inhibition Assay (5 min Preincubation) from Article 10.1021/bi701378g: \\Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.\\2007Biochemistry, Nov-13, Volume: 46, Issue:45
Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.
AID1799539Enzyme-coupled Assay from Article 10.1016/j.chembiol.2009.02.013: \\Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain.\\2009Chemistry & biology, Apr-24, Volume: 16, Issue:4
Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain.
AID1798727FAAH Inhibition Assay (60 min Preincubation) from Article 10.1021/bi701378g: \\Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.\\2007Biochemistry, Nov-13, Volume: 46, Issue:45
Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (453)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's127 (28.04)29.6817
2010's276 (60.93)24.3611
2020's50 (11.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.22 (24.57)
Research Supply Index6.12 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index48.16 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews9 (1.98%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other446 (98.02%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]